Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis

OBJECTIVE: Erlotinib plus gemcitabine is approved in Japan for the treatment of metastatic pancreatic cancer. The POLARIS surveillance study investigated safety (focusing on interstitial lung disease [ILD]) and efficacy of erlotinib plus gemcitabine in Japanese pancreatic cancer patients. METHODS: P...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuse, Junji, Gemma, Akihiko, Ichikawa, Wataru, Okusaka, Takuji, Seki, Akihiro, Ishii, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896695/
https://www.ncbi.nlm.nih.gov/pubmed/28541474
http://dx.doi.org/10.1093/jjco/hyx075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896695/
https://www.ncbi.nlm.nih.gov/pubmed/28541474
http://dx.doi.org/10.1093/jjco/hyx075

Ejemplares similares